Founded Entities

PureTech's Founded Entities include 20 products and product candidates, of which two have been cleared by the FDA and 12 are clinical stage.

All of these underlying programs and platforms were initially identified or discovered and then advanced by PureTech in collaboration with a cross-disciplinary group of experienced clinicians and the world’s leading experts.

< RETURN TO PROGRAMS

Founded Entities

>$890m

Raised with top-tier co-investors in Founded Entities since July 2018¹

Controlling Interest or Right to Receive Royalties

Developing therapies for people with severe neuropsychiatric disorders

12.8% Equity plus Royalties

PHASE 3 READY

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

KarXT

Initial Indication(s):

Schizophrenia

Patient Population:

~2.7M U.S.

Phase:

Phase 3 Ready

Initial Indication(s):

Dementia-related psychosis

Patient Population:

~1.2M U.S.

Phase:

Phase 1

More about Karuna

Targeting the GI system locally to treat the genesis of chronic disease

21.0% Equity plus Royalties

FDA CLEARED,
EUROPEAN CE MARK GRANTED

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

Plenity®^3,4

Initial Indication(s):

Weight management

Patient Population:

~150M U.S. (Overweight and obesity)

Phase:

FDA Cleared,
European CE Mark Granted

Product Candidate:

GS100^4,5

Initial Indication(s):

Adolescent weight management

Patient Population:

~13.7M U.S.

Phase:

Phase 2 Ready⁶

Product Candidate:

GS500^4,5

Initial Indication(s):

Functional constipation

Patient Population:

~35M U.S.

Phase:

Phase 3 Ready⁶

Product Candidate:

Gelesis200^4,5

Initial Indication(s):

Weight management in type 2 diabetes (T2D)/prediabetes

Patient Population:

~30M U.S. (T2D)
~84M U.S. (Prediabetes)

Phase:

Phase 2

Product Candidate:

GS300^4,5

Initial Indication(s):

Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease

Patient Population:

~80-100M U.S.

Phase:

Phase 2 Ready⁶

More About Gelesis

A regenerative platform for hair growth

78.3% Equity plus Royalties

PHASE 3 READY

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

FOL-004

Initial Indication(s):

Androgenetic alopecia

Patient Population:

~90M U.S.

Phase:

Phase 3 Ready

More About Follica

Targeting devastating GI disease

78.6% Equity

PRECLINICAL

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

ALV-306

Initial Indication(s):

Pouchitis

Patient Population:

~70K-135K U.S.

Phase:

Preclinical

Product Candidate:

ALV-304

Initial Indication(s):

Inflammatory bowel disease

Patient Population:

~3M U.S.

Phase:

Preclinical

Product Candidate:

ALV-107

Initial Indication(s):

Interstitial cystitis/Bladder pain syndrome

Patient Population:

~4-12M U.S.

Phase:

Preclinical

More About Alivio

Founded by scientific leaders in the fields of immunology and the microbiome

50.4% Equity

PHASE 2

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

VE303

Initial Indication(s):

High-risk Clostridioides difficile

Patient Population:

~100-120K/year U.S.

Phase:

Phase 2

Product Candidate:

VE416

Initial Indication(s):

Food allergy

Patient Population:

~2.5M U.S. (Peanut allergy)

Phase:

Phase 1/2

Product Candidate:

VE202

Initial Indication(s):

Inflammatory bowel disease

Patient Population:

~3M U.S.

Phase:

Phase 1

Product Candidate:

VE800

Initial Indication(s):

Solid tumors

Patient Population:

>46K/year U.S. (Advanced & metastatic MSS CRC)
>11K/year U.S. (Gastric cancers)
>9K/year U.S. (Melanoma)

Phase:

Phase 1

More About Vedanta

Unlocking voice as a vital sign and meaningful predictor of health

45.8% Equity

PHASE 1

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

Sonde One for Depression⁴

Initial Indication(s):

Depression symptom change detection and monitoring

Patient Population:

~17M U.S.

Phase:

Clinical Trials

More About Sonde

Engineering hydrogels to enable oral delivery of biologics

72.9% Equity

PRECLINICAL

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

ENT-100

Initial Indication(s):

Oral delivery of biologics, vaccines and other drugs

Patient Population:

Phase:

Preclinical

More About Entrega

Equity Interest Only

Digital therapeutics for people living with cognitive impairment

34.0% Equity

FDA CLEARED,
EUROPEAN CE MARK GRANTED

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

EndeavorRx™

Initial Indication(s):

Pediatric ADHD

Patient Population:

~6.4M U.S. (Pediatric ADHD)

Phase:

FDA Cleared,
European CE Mark Granted

Product Candidate:

AKL-T01

Initial Indication(s):

Parkinson’s/MCI

Patient Population:

Phase:

Phase 1 (Feasibility)

Initial Indication(s):

Traumatic brain injury

Patient Population:

Phase:

Phase 1 (Feasibility)

Product Candidate:

AKL-T02

Initial Indication(s):

Pediatric autism

Patient Population:

~1.5M U.S.

Phase:

Phase 2 (POC)

Product Candidate:

AKL-T03

Initial Indication(s):

Multiple sclerosis

Patient Population:

~900K U.S.

Phase:

Phase 2 (POC)

Initial Indication(s):

Major depressive disorder

Patient Population:

~17M U.S.

Phase:

Pivotal Study Ready⁷

Product Candidate:

AKL-T04

Initial Indication(s):

Major depressive disorder

Patient Population:

~17M U.S.

Phase:

Preclinical

Product Candidate:

ADHD Insight™

Initial Indication(s):

ADHD caregiver app

Patient Population:

Phase:

Released

More About Akili

Engineered hematopoietic stem cells that unleash the potential of targeted therapies

11.8% Equity

PRECLINICAL

Product Candidate

Initial Indication

Patient Population

Stage of Development

Product Candidate:

VOR33

Initial Indication(s):

Acute myeloid leukemia

Patient Population:

>20K/year U.S.

Phase:

Preclinical

More About Vor

Note: This figure represents the stage of development for each Founded Entity’s most advanced product candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of June 30, 2020, Controlled Founded Entities include Alivio Therapeutics, Inc., Follica, Incorporated, Entrega, Inc., Vedanta Biosciences, Inc. and Sonde Health, Inc., and Non-Controlled Founded Entities include Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc., and Vor Biopharma Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of June 30, 2020, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor is based on the assumption that all future tranches of the most recent financing round are funded. Karuna ownership is calculated on an outstanding voting share basis as of July 31, 2020.

1. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly.

3. Important Safety Information: Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatine, or titanium dioxide. Plenity may alter the absorption of medications. Read Sections 6 and 8.3 of the Instructions for Use carefully. Avoid use in patients with the following conditions: esophageal anatomic anomalies, including webs, diverticuli, and rings; suspected strictures (such as patients with Crohn’s disease); or complications from prior gastrointestinal (GI) surgery that could affect GI transit and motility. Use with caution in patients with active GI conditions such as gastro-esophageal reflux disease (GERD), ulcers or heartburn. The overall incidence of adverse events (AEs) in the Plenity group was no different than the placebo group. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. For the safe and proper use of Plenity, U.S. Instructions for Use or the EU Instructions for Use.

4. These product candidates are regulated as devices and their development has been approximately equated to phases of clinical development.

5. Products are investigational and have not been cleared by the FDA for use in the United States.

6. Contingent on FDA review of the research plan.

7. Future clinical research plans and priorities in process.

Cash at PureTech Parent Level

LEARN MORE

$321.5m

PureTech Level Pro-forma Cash Reserves³

$120.6m

PureTech Level Cash Reserves as of 31 December 2019⁴

$45m

Cash from KRTX Equity Sale on May 25, 2020⁵

3. PureTech Level Pro-forma Cash Reserves is an alternative performance measure (APM) which includes the PureTech Level Cash Reserves of $120.6 million and the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares. PureTech Pro-forma Cash Reserves is therefore considered to be more representative of the Corporate’s cash available for the year 2020 and beyond to advance product candidates within the full breadth of its operations.

4. PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $112.0 million for the year ended 2019 and the internal pipeline of $8.6 million for the year ended 2019, all of which are wholly-owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities. The balance excludes the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares.

5. 44.5 million in proceeds from the 22 May 2020 sale of 555.5 thousand Karuna common shares.

The BIG Idea - Moving medicine forward at PureTech

Collaborative drug discovery based on proprietary biological insights

Rapid & cost-efficient prioritization & validation

Develop internally, partner or spin-out

Collaborative drug discovery based on proprietary biological insights

Rapid & cost-efficient prioritization & validation

Develop internally, partner or spin-out

See Our Case Studies

Relationships with multiple major pharma companies or their investment arms

Meet Our Global Collaborators